Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest ...

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump ...

Eli Lilly investors will be searching for something they won't find in any first-quarter financial figures reported on ...

Eli Lilly is spending some of its GLP-1 money to buy up CAR-T gene therapy researchers. UBS analyst Michael Yee thinks that's smart strategy. So what does this Wall Street analyst like about Lilly?

Eli Lilly has agreed to buy privately held cancer biotech Kelonia Therapeutics for up to $7 billion in cash in a deal that bolsters the drugmaker's genetic-medicine capabilities. Eli Lilly on Monday ...

Eli Lilly struck a deal to acquire Kelonia Therapeutics for $3.25 billion, the companies said Monday. The deal price could reach as much as $7 billion if Kelonia reaches certain clinical, regulatory ...

Eli Lilly is partnering with the state of Indiana to explore how to add new power to the electric grid and forge a path to make nuclear energy a reality, Gov. Mike Braun announced April 16.

Eli Lilly LLY.N said on Thursday its newly approved obesity pill was not inferior to a widely used long-acting insulin at lowering the risk of major heart problems in patients with type 2 diabetes and ...

Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Pharmaceutical giant Eli Lilly acquired Houston biotechnology startup CrossBridge Bio this week in a roughly $300 million deal. The startup, which is based out of the Texas Medical Center's innovation ...